Table 5.
De novo gene mutations in synchronous and metachronous lung metastasis in relation to treatment regimens
| Case ID # | syn/met | Year of occurrence post PT | Therapy regimen | De novo mutations |
|---|---|---|---|---|
| 1 | met | 5 | Ardalan | ABL1, FGFR3, KRAS, NRAS, RET, SMARCB1, STK11, TP53, VHL |
| 3 | met | 2 | FOLFOXIRI, FOLFOXIRI/Bevacizumab, Xeloda/Bevacizumab, CAPIRI, Mitomycin, FOLFOX | AKT1, ALK, APC, ATM, CSF1R, EGFR, ERBB2, ERBB4, FBXW7, FGFR2, FGFR3, FLT3, GNA11, GNAQ, HNF1A, IDH1, JAK3, KDR, KIT, KRAS, MET, MLH1, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMO, SRC, STK11, TP53, VHL |
| 4 | met | 2 | FOLFOX, 5-FU/Mitomycin, FOLFIRI | No de novo mutations |
| 5 | syn | 2 | 3x FOLFOXIRI/Bevacizumab | APC, ATM, FBXW7, FGFR3, KIT, KRAS, PIK3CA, PTEN, RB1, SMAD4, TP53, VHL |
| 6 | met | 5 | 3x FOLFIRI/Bevacizumab, FOLFOX | SMO |
| 7 | met | 5 | FOLFOX4 | No de novo mutations |
| 8 | syn,met | 1,2 | FOLFOXIRI, FOLFOXIRI/Bevacizumab | FBXW7 |
| 9 | met | 4,5,7 | Xeloda | STK11, VHL, SMO, FBXW7, ERBB4, GNA11, PDGFRA |
| 10 | met | 6 | RCTx | No de novo mutations |
| 11 | met | 2,4 | FOLFIRI/Bevacizumab | PTEN, FBXW7 |
| 12 | met | 2 | RCTx, Xeloda, FOLFIRI/Bevacizumab, FOLFIRI | APC |
| 14 | syn | 1 | 2x FOLFOXIRI/Bevacizumab, FOLFIRI/Bevacizumab | ABL1, AKT1, APC, ATM, BRAF, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FGFR3, FLT3, GNA11, GNAQ, IDH1, KIT, MET, PIK3CA, SMAD4, SMARCB1, TP53, VHL |
The table summarizes de novo mutations per case in relation to occurrence of metastasis and treatment regimens. RCTx radio/chemotherapy, Syn synchronous, met metachronous. Note that there is no direct correlation between specific treatment regimens and the number of de novo mutations and/or genes affected by de novo mutations. Refer to main text for details